News

Cytokinetics has presented the data from two phase IIa clinical trials evaluating omecamtiv mecarbil (formerly CK-1827452), one in stable heart failure patients and one in patients with ischemic

POZEN has reported that the FDA has accepted the New Drug Application (NDA) for Vimovo (PN 400). Vimovo is a fixed-dose combination of enteric-coated naproxen, pain-relieving non-steroidal anti-inflammatory

Nuevolution has entered into a research collaboration with Novartis. Under the collaboration, Nuevolution will apply its proprietary Chemetics drug discovery technology to identify novel small molecule leads against

To support this new organizational structure the leadership changes are as follows: Spinal and Biologics, Neuromodulation, Diabetes, and Surgical Technologies Group Chris O’Connell has been promoted to the

BrainStorm Cell Therapeutics (BrainStorm) has entered into an agreement with Protein Production Services (PPS) in order to start Good Manufacturing Practice (cGMP) production of its stem cell therapeutic

Evotec has reported that the acquisition of the controlling majority stake of Research Support International (RSIPL) has been successfully completed and that RSIPL is a 70%, majority owned

BioSyent has signed an exclusive product development, supply and distribution agreement with a new partner for a new product under its Hospital Products Division. Reportedly, the product will

BioNeutral Group has signed a collaborative agreement to expand its relationship with the Chertoff Group. Under the agreement, Chertoff Group principal Jeffrey Runge, and deputy chief operating officer

The Medicines Company has reported data for HORIZONS-AMI Trial, which evaluated Angiomax for one year. The trial showed that patients who had suffered the most severe form of